/
We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging our proprietary, flexible, off-the-shelf ImmTAX ( I mmune m obilizing m onoclonal T CRs A gainst X disease) platform, we are developing a deep pipeline in multiple ther…
$34.08
$0.88 (-2.52%)
Live · 06:16 PM
The business is unprofitable at the operating level (-11.34% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 29.0% YoY with margins expanding 11.4pp. However, free cash flow softened 172%, worth monitoring whether this is timing or structural.
Free cash flow declined 172% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$15M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$413M
▲ +29.0% YoY
Net Income (TTM)
-$28M
▲ +30.5% YoY
Op. Margin
-8.35%
▲ +11.4pp YoY
ROIC
-6.28%
▲ +5.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$31M
▼ -172.1% YoY
Op. Cash Flow (TTM)
-$25M
▼ -141.1% YoY
Net Debt
-$803M
Net Cash Position
Cash & Equiv.
$845M
3Y CAGR: +31.9%
Continue Research
Immunocore Holdings (IMCR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Immunocore Holdings scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Immunocore Holdings scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -8.3% operating margin and a -6.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh IMCR's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.